Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. 2008

Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
Department of Neurosurgery, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA. aheimber@mdanderson.org

Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Although there is monthly fluctuation of the white blood cell count, specifically the CD4 and CD8 counts, there was no cumulative decline in the patient described in this case report. Depriving patients of this agent, in order to treat with immunotherapy, is controversial. Despite conventional dogma, we demonstrated that chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
October 2007, Journal of neuro-oncology,
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
May 2006, The Lancet. Oncology,
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
January 2010, Przeglad lekarski,
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
December 2015, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
August 2010, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
September 2006, Anti-cancer drugs,
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
September 2020, Immunity, inflammation and disease,
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
April 2012, Journal of medical imaging and radiation oncology,
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
January 2017, Asian journal of surgery,
Amy B Heimberger, and Wei Sun, and S Farzana Hussain, and Mahua Dey, and Lamonne Crutcher, and Ken Aldape, and Mark Gilbert, and Samuel J Hassenbusch, and Raymond Sawaya, and Bob Schmittling, and Gary E Archer, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
August 2010, Current oncology (Toronto, Ont.),
Copied contents to your clipboard!